Prostate cancer is the second most common cancer among men globally, with millions of new cases diagnosed each year. While many early-stage prostate cancers are effectively managed with hormone therapies, a significant portion of cases progresses to a more aggressive…

Castrate-resistant prostate cancer (CRPC) remains a significant challenge in oncology due to its aggressive nature and high mortality rates. As the global incidence of prostate cancer rises, advancements in CRPC therapies continue to evolve, offering new hope for patients. In…